

Laura Izquierdo Reyes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/485746/publications.pdf>

Version: 2024-02-01

36
papers

700
citations

567144

15
h-index

580701

25
g-index

39
all docs

39
docs citations

39
times ranked

1056
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after 20 years of experience in minimally invasive living-donor nephrectomy. <i>World Journal of Urology</i> , 2022, 40, 807-813.	1.2	6
2	Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 2033-2039.	1.2	11
3	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. <i>Scientific Reports</i> , 2021, 11, 6132.	1.6	7
4	Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6338.	1.7	2
5	Urine Gene Expression Profiles in Bladder Pain Syndrome Patients Treated with Triamcinolone. <i>European Urology Focus</i> , 2020, 6, 390-396.	1.6	3
6	Results and Lessons Learned on Robotic Assisted Kidney Transplantation. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	8
7	Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques. <i>Cancer Cytopathology</i> , 2020, 128, 460-469.	1.4	5
8	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020, 203, 283-291.	0.2	10
9	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 402-407.	0.9	33
10	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. <i>Translational Research</i> , 2019, 208, 73-84.	2.2	5
11	Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2019, 25, 289-299.	0.9	5
12	Prognostic value of circulating microRNAs in upper tract urinary carcinoma. <i>Oncotarget</i> , 2018, 9, 16691-16700.	0.8	16
13	Is Robotic Kidney Transplant the Near Future?. <i>European Urology</i> , 2017, 72, 218-219.	0.9	6
14	Pain relief after triamcinolone infiltration in patients with bladder pain syndrome with Hunner's ulcers. <i>International Urogynecology Journal</i> , 2017, 28, 1027-1031.	0.7	6
15	Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2017, 8, 18238-18247.	0.8	22
16	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. <i>Oncotarget</i> , 2017, 8, 51522-51529.	0.8	8
17	Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. <i>BMC Cancer</i> , 2016, 16, 76.	1.1	22
18	Intraoperative prognostic factors and atypical patterns of recurrence in patients with upper urinary tract urothelial carcinoma treated with laparoscopic radical nephroureterectomy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 305-312.	0.6	16

#	ARTICLE	IF	CITATIONS
19	The role of cystectomy in elderly patients – a multicentre analysis. BJU International, 2015, 116, 73-79.	1.3	41
20	Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU International, 2014, 113, 813-821.	1.3	29
21	Health-Related Quality of Life in Patients With Urostomies. Journal of Wound, Ostomy and Continence Nursing, 2014, 41, 254-256.	0.6	12
22	Recent advances of natural orifice transluminal endoscopic surgery in urological surgery. International Journal of Urology, 2013, 20, 462-466.	0.5	4
23	Impact of a Nurse-Run Clinic on Prevalence of Urinary Incontinence and Everyday Life in Men Undergoing Radical Prostatectomy. Journal of Wound, Ostomy and Continence Nursing, 2013, 40, 309-312.	0.6	6
24	Hypertension, dyslipidemia and overweight are related to lower testosterone levels in a cohort of men undergoing prostate biopsy. International Journal of Impotence Research, 2012, 24, 110-113.	1.0	22
25	Nursing Care Program for Erectile Dysfunction After Radical Prostatectomy. Clinical Journal of Oncology Nursing, 2012, 16, E178-E182.	0.3	5
26	Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy. World Journal of Urology, 2012, 30, 361-365.	1.2	17
27	Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU International, 2012, 110, E199-202.	1.3	28
28	Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU International, 2012, 110, E541-6.	1.3	63
29	Transvaginal NOTES and LESS: Are They the Future in Kidney Surgery?. European Urology Supplements, 2011, 10, e58-e63.	0.1	6
30	Feasibility of Transvaginal Natural Orifice Transluminal Endoscopic Surgery – Assisted Living Donor Nephrectomy: Is Kidney Vaginal Delivery the Approach of the Future?. European Urology, 2011, 59, 1019-1025.	0.9	81
31	Feasibility of Transvaginal NOTES-Assisted Laparoscopic Nephrectomy. European Urology, 2010, 57, 233-237.	0.9	94
32	Molecular characterization of upper urinary tract tumours. BJU International, 2010, 106, 868-872.	1.3	20
33	Third and Fourth Kidney Transplant: Still a Reasonable Option. Transplantation Proceedings, 2010, 42, 2498-2502.	0.3	33
34	HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Research, 2010, 30, 2439-45.	0.5	9
35	Prognostic value of IL-6 in localized prostatic cancer. Anticancer Research, 2010, 30, 4369-72.	0.5	20
36	Adhesion molecules β 1, β 2 and β 3-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT/GSK-3 β /catenin pathway. BJU International, 2009, 104, 100-106.	1.3	11